Nuochengjianhua released its 2026 three-quarter report. In the first three quarters, it achieved revenue of 2.10 billion yuan, an increase of 88.2% over the previous year; net profit of 650 million yuan, and a loss of 70 million yuan for the same period last year. Drug revenue was 1.45 billion yuan, up 41.5% year on year; R&D investment was 790 million yuan, up 16.1% year on year. In the third quarter, the company and Eli Lilly reached a strategic cooperation to jointly discover and develop up to 5 innovative target projects, with a total transaction value of up to US$3.35 billion.
Zhitongcaijing · 2d ago
Share
Listen to the news
Nuochengjianhua released its 2026 three-quarter report. In the first three quarters, it achieved revenue of 2.10 billion yuan, an increase of 88.2% over the previous year; net profit of 650 million yuan, and a loss of 70 million yuan for the same period last year. Drug revenue was 1.45 billion yuan, up 41.5% year on year; R&D investment was 790 million yuan, up 16.1% year on year. In the third quarter, the company and Eli Lilly reached a strategic cooperation to jointly discover and develop up to 5 innovative target projects, with a total transaction value of up to US$3.35 billion.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending